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Abstract Iron can be involved in the pathogenesis of
AMD through the oxidative stress because it may catalyze
the Haber–Weiss and Fenton reactions converting hydro-
gen peroxide to free radicals, which can induce cellular
damage. We hypothesized that genetic polymorphism in
genes related to iron metabolism may predispose individ-
uals to the development of AMD and therefore we checked
for an association between the g.32373708 G[A poly-
morphism (rs867469) of the IRP1 gene and the g.49520870
G[A (rs17483548) polymorphism of the IRP2 gene and
AMD risk as well as the modulation of this association by
some environmental and life-style factors. Genotypes were
determined in DNA from blood of 269 AMD patients and
116 controls by the allele-speciﬁc oligonucleotide-restric-
tion fragment length polymorphism and the polymerase
chain reaction-restriction fragment length polymorphism.
An association between AMD, dry and wet forms of AMD
and the G/G genotype of the g.32373708 G[A-IRP1
polymorphism was found (OR 3.40, 4.15, and 2.75). On the
other hand, the G/A genotype reduced the risk of AMD as
well as its dry or wet form (OR 0.23, 0.21, 0.26). More-
over, the G allele of the g.49520870 G[A-IRP2 poly-
morphism increased the risk of the dry form of the disease
(OR 1.51) and the A/A genotype and the A allele decreased
such risk (OR 0.43 and 0.66). Our data suggest that the
g.32373708 G[A-IRP1 and g.49520870 G[A-IRP2
polymorphisms may be associated with increased risk for
AMD.
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Introduction
Age-related macular degeneration (AMD) is an eye disease
that is characterized by progressive vision loss of variable
severity accompanied by distinct changes in the structure
of the retina, retinal pigment epithelium (RPE), Bruch’s
membrane and choriocapillaris [1]. Currently, AMD is
estimated to affect approximately 30 million people glob-
ally and this number is expected to triple over the next
25 years [2]. AMD ranks third among the global causes of
visual impairment with a blindness prevalence of 8.7%. It
is the primary cause of visual deﬁciency in industrialized
countries [3].
Although the pathophysiology of AMD is not clearly
understood, it is well accepted that both oxidative stress
and genetic factors in combination with environmental and
life-style factors play an important role in the pathogenesis
of the disease. The most consistent major risk factor for
AMD is age. The development of AMD is a slow pro-
gressive process that occurs with aging and mainly affects
people over age 60 [4]. While people in middle age have
about a 2% risk of getting AMD, the risk increased to
nearly 30% in those over age 75 [5]. Also, many other risk
factors, including smoking, female sex, obesity, athero-
sclerosis, white race, exposure to sunlight and consumption
of a non-balanced diet, have been proposed for AMD
development [6, 7]. Results of several studies have shown
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[8–10].
Age-related disorders, including retinal diseases may
result from cumulative oxidative damage resulting from
reactive oxygen species (ROS) [11–13]. The macula is a
source of high metabolic activity and is therefore exposed
to high levels of ROS. With age, the balance between the
production of ROS and local antioxidant levels can be
disturbed, resulting in oxidative damage to outer segments
of photoreceptors and lead to a progressive deterioration of
the RPE [14]. One source of ROS generation is iron. Iron
may catalyze the Haber–Weiss and Fenton reactions con-
verting hydrogen peroxide to free radicals, which can cause
oxidative tissue damage. AMD may be exacerbated by
retinal iron overload and histopathology of eyes with
macular degeneration has shown elevated levels of iron in
RPE, Bruch’s membrane and within drusen [15, 16].
Moreover, the concentration of retinal iron increases with
age [17]. Iron homeostasis is controlled by the regulation of
the expression of iron-regulatory proteins (IRPs), which
can bind iron-responsive elements (IREs) on the mRNA of
target proteins.
A number of epidemiological studies have implicated
AMD as an inherited disease showing that family members
are at an increased risk of the disease [18–20]. Consider-
able evidence in family, twin and sibling studies exists,
suggesting a genetic basis of AMD. Twin studies have
demonstrated that genetic factors contribute to 46–71% of
the overall variation in severity of macular degeneration.
When one or both twins have AMD, concordance for AMD
is 55% among monozygotic twins and 25% among dizy-
gotic twins [21]. Several family studies have shown that
patients with a positive family history of AMD are at
increased risk of this disease [22–24]. Interestingly, Luo
et al. [25] identiﬁed 4,764 patients with AMD and exam-
ined familial aggregation and risk of AMD in a Utah
population using a population-based case–control study.
The results showed that the population-attributable risk for
AMD was calculated to be 0.34. Recurrence risks in rela-
tives indicate increased relative risk in siblings (2.95), ﬁrst
cousins (1.29), second cousins (1.13), and parents (5.66) of
affected individuals.
In recent years, the role of genetic factors in AMD
development has been extensively investigated. Numerous
case–control studies have conﬁrmed the association
between single nucleotide polymorphisms (SNPs) and
AMD [26–28]. We hypothesized that genetic polymor-
phisms in the IRPs genes may be associated with devel-
opment of AMD. To test our hypothesis, we evaluated the
association between the g.32373708 G[A polymorphism
(rs867469) of the IRP1 gene and the g.49520870 G[A
(rs17483548) polymorphism of the IRP2 gene and AMD as
well as the modulation of this association by some
environmental and life-style factors. Both polymorphisms
are SNPs with a minor allele frequency[3% in European
population and are located in the 50 ﬂanking region of these
genes. Polymorphism in this region can affect mRNA
stability and degradation, and gene expression. [29].
Materials and methods
Study subjects and data collection
This case–control study included a total of 270 patients
with AMD and 116 disease-free control subjects. Among
AMD patients, 100 had dry AMD and the remaining 170—
wet form of this disease. Eight patients with the dry form of
the disease had geographic atrophy. The control subjects
had no clinical evidence of AMD after undergoing the
same comprehensive ophthalmic examination that was
performed to conﬁrm AMD in the patient group. Medical
history was obtained from all subjects and no one reported
current or previous cancer or any genetic disease. All
patients and controls were examined in the Department of
Ophthalmology, Medical University of Warsaw (Warsaw,
Poland). They underwent ophthalmic examination,
including best-corrected visual acuity, intraocular pressure,
slit lamp examination, and fundus examination, performed
with a slit lamp equipped with either non-contact or contact
fundus lenses. Diagnosis of AMD was conﬁrmed by optical
coherence tomography (OCT) and, in some cases, by
ﬂuorescein angiography (FA) and indocyanin green angi-
ography (ICG). OCT evaluated retinal thickness, the
presence of RPE atrophy, drusen, or subretinal ﬂuid and
intraretinal edema; angiography assessed the anatomical
status of the retinal vessels, the presence of choroidal
neovascularization and leakage. The OCT examinations
were performed with Stratus OCT model 3000, software
version 4.0 (Oberkochen, Germany). The FA and ICG
examinations were performed with a Topcon TRC-50I IX
fundus camera equipped with the digital Image Net image
system, version 2.14 (Topcon, Tokyo, Japan). An informed
written consent was signed by all participants and the study
design was approved by the Bioethics Committee of the
Medical University of Warsaw. A structured questionnaire
was used to determine demographic characteristics, family
history of AMD (ﬁrst-degree relatives), living environment
(rural or urban areas) and life-style, including smoking and
alcohol use. Each subject donated a venous blood sample
of *5 ml, 250 ll of which was used for genomic DNA
extraction. Blood samples of all patients and controls were
collected into ethylenediaminetetraacetic acid (EDTA)
tubes and stored at -20C until further use. All samples
were coded after collection of blood and completing the
questionnaire. Data on disease status, sex, age, smoking
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123history, living environmental, and family history of AMD
of the subjects enrolled in this study are presented in
Table 1.
SNP selection and primers design
There are many SNPs in the IRP1 and IRP2 genes listed in
the dbSNP short genetic variations database in the NCBI
http://www.ncbi.nlm.nih.gov/snp, but none of them has
annotated any clinical signiﬁcance and were not able to ﬁnd
any evidence for this. Our selection of polymorphisms was
made on the basis of their location in the 50 regulatory
region, which usually contains the promoter. The pheno-
typic consequences of such DNA sequence changes may be
associated with the difference in the transcription level,
which can be quantitatively assessed in future research.
Primers were designed using the IRP1 and IRP2 genomic
sequence found at http://www.ensembl.org/Homo_sapiens/
Gene/Sequence?g=ENSG00000122729;r=9:32384601-324
50834 and http://www.ensembl.org/Homo_sapiens/Gene/
Summary?g=ENSG00000136381;r=15:78730531-7879379
5;t=ENST00000258886 and Primer3Plus software (http://
www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi)
for IRP2 SNP and Web-based allele-speciﬁc primer soft-
ware (http://bioinfo.biotec.or.th/WASP/index/wasp) for
IRP1 SNP.
DNA preparation and storage
Genomic DNA was obtained from a 250 ll aliquot of
blood using a commercially available AxyPrep
TM
Blood
genomic DNA Miniprep Kit (Axygen Biosciences, Union
City, CA, USA), according to the manufacturer’s instruc-
tions. Genomic DNA was directly isolated from the white
blood cells. DNA purity and concentration were deter-
mined spectrophotometrically at 260 and 280 nm. Each
DNA sample was stored in TE buffer (5 mM Tris–HCl,
0.1 mM EDTA, pH 8.5) at -20C until analysis.
Genotyping
The genotypes of the g.32373708 G[A-IRP1 polymor-
phism were determined by the allele-speciﬁc oligonucleo-
tide-PCR method. PCR was performed in a 25 ll reaction
volume. The reaction mixture contained 50 ng of genomic
DNA, 1 U Biotools DNA polymerase (Biotools, Madrid,
Spain), 1 9 reaction buffer [750 mM Tris–HCl, pH 9.0,
500 mM KCl, 200 mM (NH4)2SO4], 0.2 mM of each
dNTP, 1.5 mM MgCl2, 0.25 lM of each primers (Meta-
bion, Martinsried, Germany). The primers designed to
detect the g.32373708 G[A SNP were as follows: allele-
speciﬁc sense oligonucleotides 50-TGCACACCTGCAAA
GAAG-30 for G variant and 50-TGCACACCTGCAAAG
Table 1 Characteristics of
AMD patients and AMD-free
control subjects enrolled in the
study
p values for a two-sides v
2 test,
p values\0.05 are in bold
Characteristics Controls AMD p
Number Frequency Number Frequency
Disease status 116
No AMD
Dry AMD 100 0.37
Wet AMD 170 0.63
Sex
Females 82 0.78 179 0.66 0.0316
Males 23 0.22 92 0.34
Age
B60 31 0.30 32 0.12 <0.001
C61 74 0.70 239 0.88
Mean ± SD 68.20 ± 10.95 72.46 ± 8.51
Range 50–88 52–93
Smoking
Ever 32 0.41 68 0.41 0.9251
Never 46 0.59 99 0.59
Living environment
Rural 32 0.38 50 0.30 0.2880
Urban 52 0.62 114 0.70
AMD in family
Yes 3 0.04 33 0.20 <0.001
No 81 0.96 130 0.80
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CTAGATGAAAGGTGGTGAGG-30. The allele-speciﬁc
oligonucleotide-restriction fragment length polymorphism
(ASO-PCR) conditions were as follows: 5 min of initial
denaturation at 95C, followed by 30 cycles of 30 s
denaturation at 95C, 30 s annealing at 56C and 1 min
extension at 72C. The ﬁnal extension step at 72C for
5 min was also included. The PCR products (237 bp) were
fractionated by electrophoresis on a 8% polyacrylamide
gel, stained with ethidium bromide and viewed under UV
light. Fig. 1 presents a representative gel from analysis of
this polymorphism.
The polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method was used to
determine the genotypes of the g.49520870 G[A-IRP2
polymorphism. PCR assay was performed in a total reac-
tion volume of 25 ll containing the same chemicals as in
the previous analysis except for primers. 360 bp length
fragments containing polymorphic site were ampliﬁed
using the following primers: sense 50-CCCCCACTTGAA
AACACG-30 and antisense 50-AGATCGTCGGACAGGA
AAAC-30. The PCR proﬁle contained an initial denatur-
ation step for 5 min at 95C, 30 cycles at 95C for 30 s,
30 s at 60C annealing temperature and 60 s at 72C and
the ﬁnal extension step for 5 min at 72C. After ampliﬁ-
cation, the 360 bp PCR products were analyzed on a 3%
agarose gel and digested with 3 U of BspTI (AﬂII)
restriction endonuclease (Fermentas, Hanover, MD, USA)
in a ﬁnal volume of 15 ll for 16 h at 37C. PCR products
with a G at the polymorphic site were digested into two 183
and 177 bp fragments, while those with A were not
because of the absence of a BspTI (AﬂII) restriction site.
The G/G genotype produced two fragments (183, 177 bp),
whereas the G/A genotype produced three fragments (360,
183, and 177 bp) and the homozygote A/A resulted in only
one fragment 360 bp. Digested PCR products were sepa-
rated by electrophoresis on a 8% polyacrylamide gel and
visualized by ethidium bromide staining using a GeneRuler
TM
100 bp (Fermentas, Hanover, MD, USA) as a size
marker. A representative gel for this polymorphism is
presented in Fig. 2. All PCR ampliﬁcations were conducted
in a C1000 Thermal Cycler (Bio-Rad Laboratories, Her-
cules, CA, USA). Positive and negative (no template)
controls were included in all sets. For quality control, we
randomly selected 10% samples for each of the two SNPs
to perform repeat assays and the results were 100%
concordant.
Statistical analysis
All statistical analyzes were performed using STATISTI-
CA 9.0 software (Statsoft, Tulsa, OK, USA) and SigmaPlot
v11.0 software (Systat Software, Inc., San Jose, CA, USA).
To compare the distributions of demographic variables and
selected risk factors between patients and controls Chi-
square test was used. Hardy–Weinberg equilibrium (HWE)
was checked using Chi-square test to compare the observed
genotype frequencies with the expected frequencies among
the case and control subjects. The v
2 analysis was also used
to test the signiﬁcance of the differences between distri-
butions of genotypes and alleles in AMD patients and
controls. The association between case–control status and
each polymorphism, measured by the odds ratio (OR) and
its corresponding 95% conﬁdence interval (CI), was esti-
mated using an unconditional multiple logistic regression
Fig. 1 Genotypes of the g.32373708 G[A-IRP1 polymorphism
(rs867469) determined by the allele-speciﬁc oligonucleotide-PCR
(ASO-PCR) method and analyzed by a 8% polyacrylamide gel
electrophoresis stained with ethidium bromide and viewed under UV
light. Lane M displays GeneRuler
TM
100 bp molecular weight marker,
lanes designated G or A show the results of ampliﬁcation with primer
speciﬁc to either the G or A allele, respectively and lane X shows a
negative control comprising reaction mixture without target DNA.
Genotypes are indicated in the lower part of the picture
Fig. 2 Genotypes of the g.49520870 G[A-IRP2 polymorphism
(rs17483548) determined by the PCR-RFLP detection and analyzed
by a 8% polyacrylamide gel electrophoresis stained with ethidium
bromide and viewed under UV light. Lane M shows GeneRuler
TM
100 bp molecular weight marker, lane X shows a negative control
comprising reaction mixture without target DNA, all remaining lanes
present genotypes indicated in the upper part of the picture
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smoking habit, living environment (rural versus urban
areas), and family status of AMD. Smoking habit was
categorized in terms of never smokers and smokers
(including current and former). Stratiﬁed analysis accord-
ing to age, sex, and family status of AMD was also con-
ducted. To study a possible gene-environment interaction,
the patients and controls were divided into subgroups
depending on sex, family history and age. Unconditional
logistic regression analyzes were also performed to assess
the association between genotypes and risk for AMD after
stratiﬁcation of the individuals according to sex, age, and
family status of AMD.
Results
Characteristics of the study population and relationship
between demographic, environmental, life-style factors,
and family history and the risk of AMD independent
of genotype
The characteristics of the patients with AMD and AMD-
free controls involved in this study are presented in Table 1.
The mean ± SD age was 72.46 ± 8.51 years for the
patients (range 52–93) and 68.29 ± 10.95 years for the
controls (range 50–88) and 34% of the patients and 23% of
the controls were men, whereas 66% of the patients and
82% of the controls were women. There were signiﬁcantly
more subjects with negative family history for AMD among
the controls than patients (96 vs. 80%, p\0.001). There-
fore, these variables were further adjusted in the multivar-
iate logistic regression model to control for possible
confounding factors of the main effects of the polymor-
phisms. Moreover, we explored the relationships between
age, sex, smoking, living environment and family history of
AMD and the risk of AMD independently of genotype. We
compared AMD patients and controls according to these
parameters (Table 2). Our results suggest that male sex (OR
1.83, 95% CI 1.08–3.10; p = 0.024), age (7.42, 95% CI
2.62–21.02, p\0.001) and ﬁrst-degree relatives with
AMD (OR 6.85, 95% CI 2.04–23.08; p = 0.002) signiﬁ-
cantly increased the risk of the disease.
Polymorphisms of the IRP1 and IRP2 genes, gene–gene
interaction and AMD occurrence and progression
The genotype and allele distributions of the g.32373708
G[A-IRP1 and g.49520870 G[A-IRP2 polymorphisms in
AMD patients and controls are summarized in Table 3. The
observed genotype frequencies of the g.49520870 G[A-
IRP2 SNP were all in agreement with the HWE calculated
for the cases and controls (p[0.05, data not shown). As
shown in Table 3 the difference in the frequency distri-
butions of genotypes of the g.32373708 G[A-IRP1 SNP
between the cases (AMD, dry and wet forms of the disease)
and controls was statistically signiﬁcant (p\0.05). An
association between AMD, dry and wet forms of AMD and
the G/G genotype of the g.32373708 G[A-IRP1 poly-
morphism was found (adjusted OR 3.40, 4.15, and 2.75,
Table 2 Risk of AMD associated with age, sex, smoking, living environment and family history of AMD
Characteristics Controls AMD OR (95% CI) p
Number (frequency) Number (frequency)
Age
From point 1.05 (1.02–1.07) <0.001
From range 7.42 (2.62–21.02) <0.001
Sex
Females 82 (0.78) 179 (0.66) 0.55 (0.32–0.92) 0.024
Males 23 (0.22) 92 (0.34) 1.83 (1.08–3.10) 0.024
Smoking
Ever (current, former) 32 (0.41) 68 (0.41) 0.99 (0.57–1.71) 0.964
Never 46 (0.59) 99 (0.59) 0.91 (0.53–1.58) 0.748
Living environment
Rural 32 (0.38) 50 (0.30) 0.71 (0.41–1.24) 0.229
Urban 51 (0.62) 114 (0.70) 1.40 (0.81–2.44) 0.229
AMD in family
Yes 3 (0.04) 33 (0.20) 6.85 (2.04–23.08) 0.002
No 81 (0.96) 130 (0.80) 0.15 (0.05–0.51) 0.002
p values\0.05 along with corresponding ORs are in bold
OR odds ratio, 95% CI
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123respectively). On the other hand, the G/A genotype reduced
the risk of AMD as well as dry form of AMD or wet form
of AMD, separately (adjusted OR 0.23, 0.21, and 0.26,
respectively). Furthermore, in the dry form of AMD, the G
allele of the g.49520870 G[A-IRP2 SNP increased the risk
of the disease (OR 1.51) and the A/A genotype and the A
allele decreased such risk (OR 0.43 and 0.66).
We also evaluated the associations between the occur-
rence of AMD and combined genotypes of the g.32373708
G[A-IRP1 and g.49520870 G[A-IRP2 polymorphisms.
The distribution of combined genotypes of these poly-
morphisms is shown in Table 4.
The presence of the A/A–G/A genotype of both poly-
morphisms increased the risk of AMD as well as its dry or
wet form, separately (OR 5.35, 6.34, and 4.74, respec-
tively), whereas the presence of the G/A–G/G genotype
decreased such risk (OR 0.36, 0.39, and 0.34, respectively).
Furthermore, the G/A–G/A genotype may have a pro-
tective effect against wet AMD and AMD (OR 0.46 and
0.42, respectively). In the wet form of AMD and AMD, the
G/G–G/A and A/A–G/G genotypes increased the risk of the
disease (OR 3.70, 3.54, 3.19, and 3.52, respectively).
Additionally, we examined the distribution of genotypes/
combined genotypes and alleles of the g.32373708 G[A-
IRP1 and g.49520870 G[A-IRP2 polymorphisms in the
group of wet AMD patients in comparison with dry AMD
patients (data not shown). Such comparison was considered
as a measure of AMD progression. We did not ﬁnd any
associationbetweentheprogressionofAMDandgenotypes/
combined genotypes and alleles of both polymorphisms.
Stratiﬁcation and interaction analysis of IRP1 and IRP2
genotypes and the risk of AMD
The association between AMD and the tested SNPs was
subjected to stratiﬁcation analysis, but only data for the
g.32373708 G[A-IRP1 are presented in Table 5 because
such analysis for other polymorphism did not yield any
signiﬁcantresult.Instratiﬁcationanalysis,theG/Ggenotype
was associatedwithasigniﬁcantlyincreasedrisk ofAMDin
subgroups of subjects of 61 years and older (adjusted OR
2.44) and women (adjusted OR 3.54). On the other hand, the
G/A genotype reduced the risk of AMD in subgroups of
subjects older than 61 years (adjusted OR 0.26), women
(adjusted OR 0.20) and smokers (adjusted OR 0.19).
Moreover, the occurrence of AMD was correlated with the
presence ofthe A/A genotype inwomen(adjusted OR2.87).
Discussion
We showed that age, sex, and family status of AMD were
signiﬁcant risk factors in the development of AMD, which
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123is in agreement with previous results obtained by others
[30, 31]. However, we did not ﬁnd any association between
smoking and AMD. At present we have not any direct
explanation of this fact except that smoking may be one of
the factor of AMD pathogenesis and not the sole reason of
AMD and the contribution of this factor depends on the
population [32]. Smoking status in our questionnaire was
deﬁned as a smoker or non-smoker without taking into
account passive smoking. It was shown that passive
smoking is associated with an almost twofold increase in
the risk of AMD for non-smokers having lived with
smokers for 5 years or more. This might explain, at least in
part, our apparently controversial data on association
between AMD and smoking [33]. Therefore, more detailed
characteristics of the population enrolled in the present
study might have shed on this apparent lack of agreement
with the established point of view.
Although the pathogenesis of AMD is not completely
understood, a growing body of evidence suggests that
oxidative stress and free radical damage may mediate or
exacerbate macular degeneration [34]. Oxidative damage is
implicated in several retinal diseases, including retinal
degeneration and AMD [35–37]. In a large clinical trial,
patients with dry AMD given dietary supplements of
antioxidants and zinc had reduced progression to advanced
AMD, suggesting that oxidative stress is somehow
involved in its pathogenesis [38]. Iron is suggested as a
potential source of oxidative radicals associated with
degenerative processes affecting the central nervous sys-
tem and the retina [34, 39, 40]. Hahn et al. [41] found that
AMD-affected maculas had signiﬁcantly increased total
iron concentration compared with age-matched controls,
suggesting that iron accumulation might play a role in this
disease. Although iron can cause oxidative tissue damage
through the Haber–Weiss and Fenton reactions, it is also an
essential for several metabolic pathway. Homeostatic reg-
ulation of ferrous iron levels is critical for meeting physi-
ologic demand while preventing the toxicity associated
with iron overload [34, 42]. Several studies have conﬁrmed
that iron overload may play a crucial role in the patho-
genesis of AMD [15, 34]. Balanced iron homeostasis is
coordinated largely at the posttranscriptional level via the
interaction of either of two IRPs with cis-regulatory RNA
motifs—IREs located in the 50 or 30 untranslated regions
(UTR) of mRNAs encoding proteins of iron uptake
[transferrin receptor 1 (TfR1) and divalent metal trans-
porter-1 (DMT-1)], export (ferroportin), utilization (5-
aminolevulinate synthase) or storage (ferritin H- and
L-chains) [43]. In mammals, two homologous IRPs have
been identiﬁed. IRP1 also known as the cytosolic aconitase
(ACO1) has two mutually exclusive functions. When iron
is abundant, IRP1 assembles an Fe–S cluster and has
Table 5 Distribution of genotypes of the g.32373708 G[A-IRP1 polymorphism stratiﬁed by age, sex and smokers in patients with dry AMD as
compared with individuals without visual disturbances (controls)
Genotype/allele Controls AMD Adjusted OR
a p
Number (frequency) Number (frequency)
Age[61 n = 67 n = 235
G/G 15 (0.22) 88 (0.37) 2.44 (1.13–5.25) 0.022
G/A 46 (0.69) 86 (0.37) 0.26 (0.13–0.53) <0.001
A/A 6 (0.09) 61 (0.26) 2.87 (1.03–7.95) 0.043
G 76 (0.57) 262 (0.56) 1.09 (0.69–1.73) 0.699
A 58 (0.43) 208 (0.44) 0.91 (0.57–1.44) 0.699
Women n = 77 n = 173
G/G 19 (0.25) 68 (0.39) 3.54 (1.60–7.84) 0.002
G/A 52 (0.67) 60 (0.35) 0.20 (0.11–0.42) <0.001
A/A 6 (0.08) 45 (0.26) 2.76 (0.95–7.98) 0.060
G 90 (0.58) 196 (0.57) 1.36 (0.82–2.24) 0.227
A 64 (0.42) 150 (0.43) 0.73 (0.44–1.21) 0.227
Smokers n = 31 n = 68
G/G 2 (0.06) 24 (0.36) 2.58 (0.77–8.59) 0.122
G/A 24 (0.77) 22 (0.32) 0.19 (0.06–0.58) 0.003
A/A 5 (0.16) 22 (0.32) 4.73 (0.94–23.69) 0.059
G 34 (0.55) 70 (0.48) 0.94 (0.46–1.92) 0.883
A 28 (0.45) 66 (0.52) 1.05 (0.51–2.14) 0.883
p values\0.05 along with corresponding ORs are in bold
a OR adjusted for age, sex and smoking
7084 Mol Biol Rep (2012) 39:7077–7087
123aconitase activity, whereas—when iron is scarce, the apo-
protein without its Fe–S cluster acquires IRE-binding
activity [44]. IRP2 also called IREB2 (iron-responsive
element binding protein 2) shares 79% homology with
IRP1 but lacks aconitase activity [45]. Mice with combined
total and constitutive deﬁciency of both IRPs show
embryonic lethality, suggesting that the IRPs are funda-
mental for life [46–48]. In both iron deﬁciency and excess,
IRP-mediated regulation rapidly restores the physiological
cytosolic iron level. Under low-iron conditions, IRPs binds
to IREs present in the 50 UTR of mRNAs, such as in ferritin
heavy and light chains and inhibits translation and con-
currently IRPs bind to mRNAs containing IREs in the 30
UTR, such as TfR1 and DMT1, resulting in increasing
RNA’s stability and levels. And vice versa, under iron high
conditions, IRP binding activity to IREs is reduced. Thus,
under iron-poor condition, IRPs upregulate genes to
increase iron uptake and under iron rich condition, IREs
upregulate genes that are required for iron storage [49–51].
The importance of normal iron homeostasis is underlined
by the fact that retinal dysfunction has been observed in
some pathological conditions due to the lack of iron or an
excess of iron [52–54].
Some results demonstrate that multiple genes and pro-
teins are involved in development of AMD. AMD can be
genetically associated with multiple susceptibility loci, i.a.
1q32 (complement factor H, CFH), 10q26 (ARMS2),
6p21.3 (complement factor B, BF; complement component
2, C2), 19p13.3–13.2 (complement component 3, C3) [55–
61]. As mentioned, both genetic predispositions and envi-
ronmental factors, such as smoking and ultraviolet rays,
play important roles in pathogenesis of AMD. Interest-
ingly, hereditary diseases of iron overload are caused by
mutations in genes of both regulation and usage [62, 63].
Furthermore, there is a growing body of evidence that
SNPs associated with inﬂammation, oxidative stress,
angiogenesis and other pathological processes have been
linked to AMD [61]. Because iron overload has been
implicated in AMD, IRPs are a strong potential candidate
for polymorphisms that could play a role in AMD. We
assessed whether the g.32373708 G[A polymorphism in
the IRP1 gene and the g.49520870 G[A polymorphism in
the IRP2 gene increase the risk of AMD. To our knowl-
edge, the g.32373708 G[A-IRP1 polymorphism and the
g.49520870 G[A-IRP2 polymorphism have not been
studied in AMD patients so far. We observed, for the ﬁrst
time, that the occurrence of AMD was positively correlated
with the presence of the G/G genotype of the IRP1 SNP
and of the G allele of the IRP2 SNP.
In conclusion, our work shows that genetic polymor-
phisms of the IRPs genes may be associated with devel-
opment of AMD. These ﬁndings may be helpful in
increasing our understanding of the etiology of AMD.
Identiﬁcation of genetic risk factors for AMD is the ﬁrst
step towards earlier detection and prevention, and in the
future, better treatments.
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